With the traditional pharmaceutical commercial model in disarray, companies are looking for new approaches to maintaining their competitive position. They're talking about--and in some cases implementing--"new commercial models," which rely heavily on reorganizing sales and marketing organizations by region, decreasing emphasis on one-on-one physician relationships, and paying more attention to building business-to-business relationships with diverse stakeholders, notably payors-including public and private payors and employers--and patient advocacy groups.
by Wendy Diller
In the early 1990s, worried about the fledgling managed care industry and Clinton administration health care initiatives, Bristol-Myers Squibb Co., like some of its peers, opted to change its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.